Shadi Tabibian: Improving Outcomes Through Accurate VWD Subclassification
Shadi Tabibian, Deputy of research at Blood Diseases Research Centers in Iran University of Medical Sciences, shared a post on LinkedIn:
“Type 1C von Willebrand disease has now been formally incorporated into the updated VWD classification following strong endorsement by the ISTH VWF SSC.
This important step recognizes increased VWF clearance as a distinct pathophysiological mechanism and may improve diagnostic precision, treatment selection, clinical research, and patient access to appropriate therapies.
Key clinical implications include:
- VWF half-life of approximately 1–3 hours after DDAVP
- VWFpp/VWF: Ag ratio greater than 3 as a supportive diagnostic marker
- Potentially inadequate or short-lived response to DDAVP
- Consideration of VWF concentrate for major bleeding or surgery
A standardized Type 1C classification provides a clearer framework for diagnosis, registries, clinical trials, and personalized management of patients with von Willebrand disease.”

Other posts featuring Shadi Tabibian on Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments